Kanagawa, Japan

Masahiro Mineno

This inventor holds 1 USPTO granted patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Mineno. Retrieved from https://idiyas.com/inventor/masahiro-mineno-61wxtbd6

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masahiro Mineno: Innovator in Cationic Lipid Technology

Introduction

Masahiro Mineno is a prominent inventor based in Kanagawa, Japan. He is known for his significant contributions to the field of pharmaceutical sciences, particularly in the development of cationic lipids. His work has implications for drug delivery systems and therapeutic applications.

Latest Patents

Masahiro Mineno holds 1 patent related to cationic lipids. This innovation showcases his expertise and commitment to advancing pharmaceutical technology.

Career Highlights

Mineno is currently employed at Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His role at Takeda allows him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, Masahiro Mineno has worked alongside notable colleagues, including Satoru Matsumoto and Yoshimasa Omori. These collaborations have fostered a dynamic environment for innovation and development.

Conclusion

Masahiro Mineno's work in cationic lipid technology exemplifies the impact of dedicated inventors in the pharmaceutical industry. His contributions continue to shape the future of drug delivery systems and therapeutic advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…